Trial Profile
To evaluate whether mild and moderate hepatic impairment have a relevant impact on Upadacitinib Pharmacokinetics
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2019
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- 11 Apr 2019 Results published in the Journal of Clinical Pharmacology
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
- 11 Jul 2018 New trial record